专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013116730A1 COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS 审中-公开
标题翻译：包含TENOFOVIR ALAFENAMIDE HEMIFUMARATE和COBICISTAT在治疗病毒感染中的联合治疗
公开(公告)号：WO2013116730A1
公开(公告)日：2013-08-08
申请号：PCT/US2013/024451
申请日：2013-02-01
申请人： GILEAD SCIENCES, INC.
发明人： RAMANATHAN, Srinivasan
IPC分类号： A61K31/35 , A61K31/513 , A61K31/5377 , A61K31/675 , A61P31/12
CPC分类号： A61K31/675 , A61K31/35 , A61K31/47 , A61K31/513 , A61K31/5377 , A61K2300/00
摘要： The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-l- (isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed.
摘要翻译：使用{9 - [（R）-2 - [[（S） - [[（S）-1-（异丙氧基羰基）乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤（替诺福韦甲酰胺半富马酸盐）与同位异构体组合。此外，公开了替诺福韦甲酰胺半富马酸盐，同位异构体，恩曲他滨和埃维伐他韦的组合以及替诺福韦甲酰胺半富马酸盐，扁桃体，恩曲他滨和达瑞那韦的组合。

2. 发明申请

WO2013116720A1 COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS 审中-公开
标题翻译：包含TENOFOVIR ALAFENAMIDE HEMIFUMARATE和COBICISTAT的组合治疗用于治疗病毒感染
公开(公告)号：WO2013116720A1
公开(公告)日：2013-08-08
申请号：PCT/US2013/024438
申请日：2013-02-01
申请人： GILEAD SCIENCES, INC.
发明人： RAMANATHAN, Srinivasan
IPC分类号： A61K31/513 , A61K31/5377 , A61K31/675 , A61K31/47 , A61P31/12
CPC分类号： A61K31/675 , A61K31/35 , A61K31/47 , A61K31/513 , A61K31/5377 , A61K2300/00
摘要： The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-l- (isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed.
摘要翻译：使用半富马酸盐形式的{9 - [（R）-2 - [[（S） - [[（S）-1-（异丙氧基羰基）乙基]氨基]苯氧基氧膦基]甲氧基] 丙基]腺嘌呤}（替诺福韦艾拉酚胺半反丁烯二酸盐）与cobicistat组合。此外，还公开了替诺福韦艾拉酚胺半反丁烯二酸盐，cobicistat，恩曲他滨和埃维替拉韦以及替诺福韦艾拉酚胺半反丁烯二酸盐，cobicistat，恩曲他滨和地瑞那韦的组合。

3. 发明申请

WO2023076332A1 INJECTABLE LIQUID PHARMACEUTICAL COMPOSTION CONTAINING GEMCITABINE AND A CYTIDINE DEAMINASE INHIBITOR 审中-公开
公开(公告)号：WO2023076332A1
公开(公告)日：2023-05-04
申请号：PCT/US2022/047811
申请日：2022-10-26
申请人： ST. JOHN'S UNIVERSITY
发明人： PATEL, Ketankumar, Dilipkumar , PATKI, Manali, Pramod
IPC分类号： A61K31/7068 , A61K45/06 , A61P35/00 , A61K9/00 , A61K47/34
摘要： The present invention relates to the development of a subcutaneous formulation of a combination of nucleoside, Gemcitabine and Zebularine. For immediate release formulation gemcitabine and zebularine may be formulated in saline solution. For extended-release formulation microparticles of gemcitabine and zebularine may be utilized, or a solution forming in-situ depot may be prepared.

4. 发明申请

WO2023009257A1 METHOD FOR MEASURING COPD BIOMARKERS DESMOSINE AND ISODESMOSINE 审中-公开
公开(公告)号：WO2023009257A1
公开(公告)日：2023-02-02
申请号：PCT/US2022/034974
申请日：2022-06-24
申请人： ST. JOHN'S UNIVERSITY
发明人： FAGIOLA, Michael , CANTOR, Jerome
IPC分类号： G01N33/68 , G01N30/72
摘要： The invention pertains to the use of a specific biomarker of elastin degradation (desmosine) that measures the extent and progression of chronic obstructive pulmonary disease (COPD). In addition to potentially serving as a screening procedure for C( )Pi ). it provides a real-time measure of COPD drug efficacy and may therefore supersede the use of less sensitive tests such as pulmonary function studies and computed tomography. Equally important, the current invention constitutes a marked improvement for measuring desmosine in tissues and body fluids by greatly shortening the time for detection of this molecule in liquid chromatography-tandem mass spectrometry (LC-MS-MS) assays that are the gold standard for such measurements. Unlike previous methods, the invention allows for the use of LC -MS-MS without modification, so the method can be applied to any laboratory that uses this equipment for other measurements. This would include forensic facilities that need to determine if undiagnosed COPD played a role in the loss of life.

5. 发明申请

WO2020046881A1 A DEVICE AND A METHOD FOR EXTREME PARTICLE HEATING 审中-公开
公开(公告)号：WO2020046881A1
公开(公告)日：2020-03-05
申请号：PCT/US2019/048266
申请日：2019-08-27
申请人： ST. JOHN'S UNIVERSITY
发明人： FORTMANN, Charies, Michael
IPC分类号： G21B3/00 , H01K1/04 , H01K1/62
摘要： A device and a method of heating nano- to micro-scale light absorbent particles within a flashtube designed to sequentially emit intense light, followed by an intense pressure wave. The flashtube device includes a housing and a central filament surrounded by the housing. An inner surface of the housing can be coated with light-scattering particles and/or light-absorbing particles. The filament is generally held in a superconducting state.

6. 发明申请

WO2017040916A2 METHODS FOR REDUCTION OF PATHOLOGICAL FIBROSIS AND ASSOCIATED DISORDERS AND DISEASES 审中-公开
标题翻译：减少病理性纤维化和相关疾病和疾病的方法
公开(公告)号：WO2017040916A2
公开(公告)日：2017-03-09
申请号：PCT/US2016/050095
申请日：2016-09-02
申请人： EVOTEC AG , THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
发明人： ANDAG, Uwe , HUMPHREYS, Benjamin, D.
IPC分类号： A61K31/7105
CPC分类号： A61K31/711 , A61K31/7105 , A61K31/713 , A61K39/395
摘要： Agents and methods for treating, reducing or ameliorating pathological fibrosis and disease or disorders caused by or associated with excessive deposition of fibrous tissue, and methods of identifying suitable agents. Preferred agents modulate the level and/or activity of GPR124.
摘要翻译：用于治疗，减轻或改善由纤维组织过度沉积引起或与之相关的病理性纤维化和疾病或病症的药剂和方法，以及鉴定合适试剂的方法。优选的药剂调节GPR124的水平和/或活性。

7. 发明申请

WO2014031352A1 DENTAL POSITIONING SYSTEM 审中-公开
标题翻译：牙科定位系统
公开(公告)号：WO2014031352A1
公开(公告)日：2014-02-27
申请号：PCT/US2013/054093
申请日：2013-08-08
申请人： SIRONA DENTAL., INC.
发明人： ABRAMOVICH, Mark , BRATSLAVSKY, Aaron , GOLDSTONE, Joe , MITA, Steven
IPC分类号： A61B6/14 , A61C19/04 , G03B42/04
CPC分类号： A61B6/145 , A61B6/4435 , G03B42/042
摘要： A dental positioning system (100) and method employing the system (100) are described. The system (100) includes at least one receptor holder (104) having an arm (112) extending from a receptor grip (114). The receptor grip (114)retains a receptor (122) in a fixed position within the receptor grip (114) and with respect to the arm. (112) The system (100) also includes an alignment ring (110) having a window (108) formed therein and having at least one opening (106) corresponding to the at least one receptor holder (104). The opening (108) is constructed to receive the arm (112) of the receptor holder (104) such that the receptor (122) is substantially centered with respect to the window(108).
摘要翻译：描述了牙科定位系统（100）和采用该系统（100）的方法。系统（100）包括至少一个具有从接收器夹持器（114）延伸的臂（112）的接收器保持器（104）。受体夹持器（114）将受体（122）保持在受体夹持器（114）内并相对于臂的固定位置。（112）系统（100）还包括其中形成有窗口（108）的对准环（110），并具有至少一个对应于至少一个接收器支架（104）的开口（106）。开口（108）被构造成容纳接收器保持器（104）的臂（112），使得接收器（122）相对于窗口（108）基本上居中。

8. 发明申请

WO2004019949A1 ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING RESTLESS LEGS SYNDROME OR RELATED DISORDERS 审中-公开
标题翻译：腺苷A2A受体拮抗剂治疗无症状综合症或相关疾病
公开(公告)号：WO2004019949A1
公开(公告)日：2004-03-11
申请号：PCT/US2003/026644
申请日：2003-08-27
申请人： KYOWA HAKKO KOGYO CO. LTD. , KASE, Hiroshi , SENO, Naoki , MORI, Akihisa , ZHAO, Dayao
发明人： KASE, Hiroshi , SENO, Naoki , MORI, Akihisa , ZHAO, Dayao
IPC分类号： A61K31/522
CPC分类号： A61K31/00 , A61K31/522
摘要： The present invention provides methods of treating restless legs syndrome or related disorders, comprising administering an effective amount of at least one adenosine A 2A receptor antagonist to a patient in need thereof. More preferably the adenosine A 2A receptor antagonist is a xanthine derivative or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了治疗不宁腿症状或相关病症的方法，包括向有需要的患者施用有效量的至少一种腺苷A 2A受体拮抗剂。更优选地，腺苷A 2A受体拮抗剂是黄嘌呤衍生物或其药学上可接受的盐。

9. 发明申请

WO2018236590A1 CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DETERMINING THE PROGRESSION RATE OF PARKINSON'S DISEASE 审中-公开
公开(公告)号：WO2018236590A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/036380
申请日：2018-06-07
申请人： ST. JOHN'S UNIVERSITY
发明人： MOLLER, Simon Geir , BASAK, Indranil , PATIL, Ketan , LARSEN, Jan Petter , ALVES, Guido Werner
IPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PrognomiRs) can be used to differentiate patient's suffering from rapid progressing Parkinson's disease (PD) from slow progressing PD patients.

10. 发明申请

WO2018236589A1 CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR ALZHEIMER'S DISEASE DIAGNOSIS 审中-公开
公开(公告)号：WO2018236589A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/036377
申请日：2018-06-07
申请人： ST. JOHN'S UNIVERSITY
发明人： MOLLER, Simon, Geir , PATIL, Ketan , ALVES, Guido, Werner
IPC分类号： C12Q1/6883
摘要： Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PARKmiRs) can be used to differentiate patient's suffering from Alzheimer's disease (AD) from non-AD patients.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式